Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C; Study Alliance Leukemia (SAL). Wass M, et al. Among authors: schlenk rf. Leukemia. 2021 Mar;35(3):701-711. doi: 10.1038/s41375-020-0892-z. Epub 2020 Jun 19. Leukemia. 2021. PMID: 32561840 Free PMC article. Clinical Trial.
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Fröhling S, Döhner K, Haas R, Döhner H; AML Study Group Ulm (AMLSG ULM). Schlenk RF, et al. Leukemia. 2003 Aug;17(8):1521-8. doi: 10.1038/sj.leu.2403009. Leukemia. 2003. PMID: 12886238 Clinical Trial.
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Götze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Döhner K, Haas R, Döhner H; AML Study Group Ulm. Schlenk RF, et al. Leukemia. 2004 Nov;18(11):1798-803. doi: 10.1038/sj.leu.2403528. Leukemia. 2004. PMID: 15385923 Clinical Trial.
Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML.
Stelljes M, Corbacioglu A, Schlenk RF, Döhner K, Frühwald MC, Rossig C, Ehlert K, Silling G, Müller-Tidow C, Juergens H, Döhner H, Berdel WE, Kienast J, Koschmieder S. Stelljes M, et al. Among authors: schlenk rf. Leukemia. 2011 Jul;25(7):1209-10. doi: 10.1038/leu.2011.64. Epub 2011 Apr 1. Leukemia. 2011. PMID: 21455213 No abstract available.
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.
Damm F, Bunke T, Thol F, Markus B, Wagner K, Göhring G, Schlegelberger B, Heil G, Reuter CW, Püllmann K, Schlenk RF, Döhner K, Heuser M, Krauter J, Döhner H, Ganser A, Morgan MA. Damm F, et al. Among authors: schlenk rf. Leukemia. 2012 Feb;26(2):289-95. doi: 10.1038/leu.2011.200. Epub 2011 Aug 9. Leukemia. 2012. PMID: 21826063
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L. Rücker FG, et al. Among authors: schlenk rf. Leukemia. 2013 Feb;27(2):353-61. doi: 10.1038/leu.2012.208. Epub 2012 Jul 19. Leukemia. 2013. PMID: 22810507
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.
Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Råcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ. Cornelissen JJ, et al. Among authors: schlenk rf. Nat Rev Clin Oncol. 2012 Oct;9(10):579-90. doi: 10.1038/nrclinonc.2012.150. Epub 2012 Sep 4. Nat Rev Clin Oncol. 2012. PMID: 22949046 Review.
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D. Braulke F, et al. Among authors: schlenk rf. Leuk Res. 2013 Aug;37(8):900-6. doi: 10.1016/j.leukres.2013.03.019. Epub 2013 Apr 25. Leuk Res. 2013. PMID: 23623559 Clinical Trial.
258 results